Antibodies

19 April 2023

Palleon Pharmaceuticals Presents Initial Phase 1 Results from the GLIMMER-01 Clinical Trial for E-602, the First Ever Glyco-Immune Checkpoint Inhibitor

19 April 2023

Mythic Therapeutics Presents Preclinical Data on Investigational cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 at American Association for Cancer Research (AACR) Annual Meeting

18 April 2023

Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023

18 April 2023

Pyramid Biosciences and GeneQuantum Healthcare Announce Preclinical Data for GQ1010, a Potential Best-In-Class TROP2-Targeted Antibody Drug Conjugate, at the 2023 AACR Annual Meeting

18 April 2023

Orum Therapeutics Unveils New Program at AACR 2023, Highlighting Cbl-b Inhibitor-PD-1 Conjugate, and Presents New Data Supporting Clinical Development of Two GSPT1 Programs Orum’s new program in immuno-oncology achieves simultaneous blockade of PD-1

18 April 2023

XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

18 April 2023

Araris Biotech AG Acquires ARS Pharmaceutical’s Nectin-4 Antibody

18 April 2023

Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi

18 April 2023

Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023

18 April 2023

Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

18 April 2023

OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio

18 April 2023

Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting

18 April 2023

Alligator Bioscience Announces Poster Presentation on ATOR-4066 at the AACR Annual Meeting 2023

17 April 2023

aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting

17 April 2023

Convergent Therapeutics Announces Updates on its Lead Therapeutic Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023

17 April 2023

Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting

17 April 2023

ZielBio to Present New Research on the Utility of Cancer-Specific Plectin (CSP) and ZB131 in Antibody-Drug Conjugates at AACR Annual Meeting 2023

17 April 2023

Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023

17 April 2023

Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)

17 April 2023

Lassen Therapeutics Presents Data Demonstrating Anti-IL18 Binding Protein Antibody Efficacy and Enhancement of Anti-Tumor Immunity at AACR Annual Meeting

17 April 2023

AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023

17 April 2023

23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

17 April 2023

Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

17 April 2023

Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023

17 April 2023

Imfinzi-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

17 April 2023

Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study

17 April 2023

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer

17 April 2023

Faron Pharmaceuticals Announces BEXMAB Study Update

15 April 2023

Results from Astellas’ Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet

14 April 2023

Alvotech Provides Regulatory Update on AVT02 Biologics License Application

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Mesothelin-Targeted Immunotherapy Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Adalimumab (Humira) Biosimilars Pipeline Review